Covaxin Phase 3 Clinical Trial shows 81% efficacy

Covaxin shows interim vaccine effectiveness of 81% in preventing the coronavirus

In a recent media release by the Indian council of medical research states, the Covaxin – First Covid-19 Vaccine wholly made in India in partnership with Bharat Biotech International Limited shows interim vaccine effectiveness of 81% in preventing the coronavirus. COVAXIN shows the ability to neutralize the UK Variant Strain of COVID-19, also established recently.

The Phase 3 trial includes a total of 25,800 individuals across 21 sites. Covaxin developed by the WHO prequalified guidelines, which is globally recognized as the track record of safety. The follow-up of the phase 3 trial with the individuals is still going on until the period of phase 3 trial.